Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a
wide range of therapeutically promising pharmacological effects either as a sole drug or in …

Some of the most compelling evidence supporting an association between cannabinoid
agonists and psychosis comes from controlled laboratory studies in humans. Randomized …

Cannabidiol (CBD), a constituent of cannabis with few psychoactive effects, has been
reported in some studies to attenuate certain aspects of Δ 9-tetrahydrocannabinol (THC) …

There is urgent need for the development of mechanistically different and less side-effect
prone antipsychotic compounds. The endocannabinoid system has been suggested to …

Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been
associated with a range of acute and chronic mental health problems, such as anxiety …

Anxiety and trauma-related disorders are psychiatric diseases with a lifetime prevalence of
up to 25%. Phobias and post-traumatic stress disorder (PTSD) are characterized by …

There have been extensive policy shifts in the legality of recreational and therapeutic use of
cannabis in the United States, as well as a steady increase in the number of people using …

Cannabidiol (CBD) has been established to have both acute and long-lasting effects to
reduce fear memory expression. The long-lasting impact might be mediated by an …

Parkinson's disease (PD), a neurodegenerative disorder, is the second most common
neurological illness in United States. Neurologically, it is characterized by the selective …

The aim of this article is to summarize current evidence regarding alterations in the
neuroendocrine stress response system and endocannabinoid system and their relationship …